GSK plc vs Invesco S&P 500 Low Volatility ETF — how do they compare? GSK plc trades at $50.13 (market cap $102.60B), while Invesco S&P 500 Low Volatility ETF trades at $75.74. The key difference: GSK plc pays a 3.57% dividend while Invesco S&P 500 Low Volatility ETF pays none, and Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | SPLV | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | — |
52-Week High | $61.18 | $77.97 |
52-Week Low | $38.22 | $70.30 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
SPLV trades at $75.63, down slightly by 0.09% with a bullish technical signal supported by moving averages. The ETF maintains quarterly dividend payments of $0.14 and shows strong institutional interest amid market volatility concerns. Recent news highlights growing investor focus on low-volatility strategies as geopolitical tensions and AI bubble fears drive demand for stability-oriented investments.
The outlook remains positive as low-volatility ETFs gain traction during uncertain market conditions. Key opportunities include defensive positioning and consistent dividend income, while risks center on potential underperformance during strong bull markets and concentration in specific sectors. The ETF's historical resilience during downturns supports its defensive appeal.
Trailing returns across standard periods
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →